SCHEMBL10141791

SCHEMBL10141791

CC1(C)OC2=C(CC1O)C(=O)C(=O)c1ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 15/20 0.55
KDM4E B2RXH2 3/20 0.55
NQO1 P15559 2/20 0.55
MALT1 Q9UDY8 2/20 0.55
ALDH1A1 P00352 2/20 0.55
CYP3A4 P08684 2/20 0.55
MAPT P10636 2/20 0.55
MEN1 O00255 1/20 0.55
CES2 O00748 1/20 0.55
GMNN O75496 1/20 0.55
TDP2 O95551 1/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
CYP1A2 P05177 1/20 0.55
GLA P06280 1/20 0.55
CYP2D6 P10635 1/20 0.55
HSPD1 P10809 1/20 0.55
THRB P10828 1/20 0.55
CYP2C9 P11712 1/20 0.55
ALOX15 P16050 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30076102 0.90 IDO1 (0.56) IDO1KDM4ENQO1MALT1ALDH1A1
SCHEMBL18791102 0.84 IDO1 (0.56) IDO1KDM4ENQO1MALT1ALDH1A1
SCHEMBL416868 0.79 IDO1 (0.46) IDO1KDM4ENQO1MALT1ALDH1A1
SCHEMBL14439387 0.75 IDO1 (0.44) IDO1KDM4ENQO1MALT1ALDH1A1
SCHEMBL14439350 0.74 IDO1 (0.43) IDO1KDM4ENQO1MALT1ALDH1A1
SCHEMBL14439344 0.74 IDO1 (0.43) IDO1KDM4ENQO1MALT1ALDH1A1
SCHEMBL20811248 0.74 IDO1 (0.59) IDO1KDM4ENQO1MALT1ALDH1A1
Nor-Beta-Lapachone SCHEMBL107599 0.73 MALT1 (0.71) IDO1KDM4ENQO1MALT1ALDH1A1
SCHEMBL104948 0.73 IDO1 (0.45) IDO1KDM4ENQO1MALT1ALDH1A1
SCHEMBL104950 0.73 IDO1 (0.45) IDO1KDM4ENQO1MALT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027161-A1 BACTERIAL STRAINS FOR TREATING DISEASE MICROBA IP PTY LTD (AU) 2026-01-29 US disclosed
WO-2023227757-A1 QUINONE PROTECTED FORMS AND CONJUGATES CAMBRIDGE ENTERPRISE LIMITED (GB) 2023-11-30 WO disclosed
US-20210161855-A1 5-LIPOXYGENASE ANTAGONISTS Instituto de Medicina Molecular João Lobo Antunes (PT) 2021-06-03 US disclosed
US-10968196-B2 Substituted β-lapachones for treating cancer University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-04-06 US disclosed
US-20200095220-A1 Substituted Beta-Lapachones and Uses Therefor UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-03-26 US disclosed
US-10450289-B2 Substituted β-lapachones for treating cancer University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-10-22 US disclosed
WO-2019050422-A1 5-LIPOXYGENASE ANTAGONISTS INSTITUTO DE MEDICINA MOLECULAR (PT) 2019-03-14 WO disclosed
US-20180170895-A1 Mitochondria-Targeted Lapachone Compounds and Uses Therefor UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2018-06-21 US disclosed
US-20180170895-A1 Mitochondria-Targeted Lapachone Compounds and Uses Therefor UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2018-06-21 US disclosed
WO-2016200934-A1 MITOCHONDRIA-TARGETED LAPACHONE COMPOUNDS AND USES THEREFOR UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-12-15 WO disclosed
EP-2655344-B1 NOVEL PHENAZINE DERIVATIVES AND THEIR USE UNIV CATHOLIQUE LOUVAIN (BE) 2015-11-25 EP disclosed
US-9181265-B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2015-11-10 US disclosed
US-9181265-B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2015-11-10 US disclosed
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES UNIVERSITE LIBRE DE BRUXELLES (BE) 2013-10-31 US disclosed
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES UNIVERSITE LIBRE DE BRUXELLES (BE) 2013-10-31 US disclosed
WO-2012085222-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USE UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2012-06-28 WO disclosed
US-7253207-B2 Quinones as disease therapies CELLGATE, INC. (US) 2007-08-07 US disclosed
US-7253207-B2 Quinones as disease therapies CELLGATE, INC. (US) 2007-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10968196-B2 Substituted β-lapachones for treating cancer NLN, NDUFB7, NDUFB5 IDO1 3725/4885KDM4E 4216/4885NQO1 21/4885
US-10450289-B2 Substituted β-lapachones for treating cancer TFAM, NLN, COX5A IDO1 4302/4885KDM4E 3656/4885NQO1 59/4885
US-20210161855-A1 5-LIPOXYGENASE ANTAGONISTS ALOX5, ALOX15, ALOX15B IDO1 342/4885KDM4E 1552/4885NQO1 85/4885
US-20180170895-A1 Mitochondria-Targeted Lapachone Compounds and Uses Therefor HADHA, TFAM, NDUFAB1 IDO1 3778/4885KDM4E 4372/4885NQO1 44/4885
US-20200095220-A1 Substituted Beta-Lapachones and Uses Therefor NLN, HADHA, HADHB IDO1 3971/4885KDM4E 4240/4885NQO1 35/4885
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES VEGFA, KDR, FLT4 IDO1 2619/4885KDM4E 1618/4885NQO1 1052/4885
US-20260027161-A1 BACTERIAL STRAINS FOR TREATING DISEASE VIP, SI, ALPI IDO1 279/4885KDM4E 4679/4885NQO1 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.